Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June to settle a case in federal court for $40 million that had been brought by 2,625 people living with HIV.

Stockley Park, UK – 3 June 2024 – Kite, a Gilead Company, announced data from a pilot study in collaboration with Dana-Farber Cancer Institute, that demonstrate Yescarta ® (axicabtagene ciloleucel) is ...

A $4.9 billion hole has appeared in Gilead Sciences' pipeline. After years of setbacks, the Big Biotech dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the ...

Gilead Sciences Inc.’s stock dipped 0.2% in after-hours trading Thursday, after the drug company’s adjusted first-quarter profit was narrower than expected. Gilead GILD posted a net loss of 4. ...

Gilead is headquartered in Foster City, California, with additional UK sites in central London, Cambridge and Stockley Park, Uxbridge. MiroBio was originally spun out of Oxford University in 2019 and ...

Arcus Biosciences and Gilead Sciences are rethinking their TIGIT strategy. Gilead is stopping a phase 3 lung cancer TIGIT clinical trial—and walking away from another project—but reaffirming ...